{
  "schemaVersion": 1,
  "id": "research-390",
  "slug": "390-what-basal-insulin-studies-tell-us-about-the-limits-of-an-add-on-result",
  "title": "What basal insulin studies tell us about the limits of an add-on result",
  "catalogLabel": "TIRZ / IGF-1 LR3",
  "productCollection": "https://heritagebiolabs.com/research-library/products/tirz-igf-1-lr3",
  "productHandles": [
    "tirz-igf-1-lr3-712",
    "tirz-igf-1-lr3-713"
  ],
  "productUrls": [
    "https://heritagebiolabs.com/product/tirz-igf-1-lr3-712",
    "https://heritagebiolabs.com/product/tirz-igf-1-lr3-713"
  ],
  "readingFocus": "Interpreting evidence",
  "readingFocusNote": "Reading focus is a navigational tag, not an evidence grade.",
  "wordCount": 261,
  "sourceYears": [
    2023,
    2026
  ],
  "paragraphs": [
    "Peptides are short chains of amino acids joined by peptide bonds. Some carry signals that help regulate glucose. Tirzepatide activates GIP and GLP-1 receptors. IGF-1 LR3 is a modified insulin-like growth factor protein. A 2026 analysis examined tirzepatide added to basal insulin and shows why an add-on result has to be read with the exact background treatment in view. [1, 2, 3]",
    "Basal insulin supplies background insulin between meals and overnight. The analysis used two trials in adults with type 2 diabetes whose glucose remained above target while receiving basal insulin. One trial compared the addition of tirzepatide with placebo. The other compared it with addition of a rapid-acting insulin. The two comparisons provided different ways to ask what happened when a treatment was added to a common background. [1]",
    "The analysis reported changes in HbA1c and fasting glucose among participants receiving tirzepatide. It also examined clinically significant episodes of low blood sugar. The authors considered whether the frequency of those episodes varied with participants’ starting characteristics, including age and duration of diabetes. Average glucose and episodes of unusually low glucose were recorded as different outcomes. [1]",
    "IGF-1 LR3 was not the background insulin or the added intervention in these trials. Its name refers to a growth-factor analog, which is a different molecule from the insulins in the study. The observed glucose and safety results describe tirzepatide under the tested insulin protocols. They cannot predict the frequency or severity of low glucose with the catalog pair, which would require a comparison that explicitly studies those two ingredients together. [1, 2, 3]"
  ],
  "sources": [
    {
      "number": 1,
      "citation": "Harpreet S. Bajaj et al. Tirzepatide as an Add-on for Participants with Inadequate Glycemic Control Using Basal Insulin: Pooled Subgroup Analysis of SURPASS-5 and -6. Diabetes Therapy (publication 2026-04-10).",
      "url": "https://pubmed.ncbi.nlm.nih.gov/41961454/"
    },
    {
      "number": 2,
      "citation": "U.S. Food and Drug Administration. MOUNJARO (tirzepatide) injection, prescribing information. Drugs@FDA (publication 2026-08).",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215866s044s045lbl.pdf"
    },
    {
      "number": 3,
      "citation": "Z. Lu et al. Recombinant expression of IGF-1 and LR3 IGF-1 fused with xylanase in Pichia pastoris. Applied Microbiology and Biotechnology (publication 2023-06).",
      "url": "https://pubmed.ncbi.nlm.nih.gov/37261455/"
    }
  ],
  "canonicalUrl": "https://heritagebiolabs.com/research-library/articles/390-what-basal-insulin-studies-tell-us-about-the-limits-of-an-add-on-result",
  "markdownUrl": "https://heritagebiolabs.com/research-library/data/articles/390-what-basal-insulin-studies-tell-us-about-the-limits-of-an-add-on-result.md",
  "jsonUrl": "https://heritagebiolabs.com/research-library/data/articles/390-what-basal-insulin-studies-tell-us-about-the-limits-of-an-add-on-result.json",
  "provenance": {
    "sourceArchive": "Peptide Research Articles - All 82 Volumes.zip",
    "sourceArchiveSha256": "9796bec477cbe2f8017dda81c7e58260985a13bdda1f934e8eb8d0549c2cada5",
    "sourceVolume": "Peptide Research Articles 078 - TIRZ GLP-2 and TIRZ IGF-1 LR3.docx",
    "sourceArticleNumber": 390,
    "contentSha256": "92da21b09044e3a6e5c3a8ad58163dd6b41330dca09c143dee442c786993ba97",
    "statement": "Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed."
  },
  "scope": "Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend."
}
